Innovation in Biological Indicator Evaluator Resistometer Vessel Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Innovation in Biological Indicator Evaluator Resistometer Vessel Technology
The authors examine advances in the design and the application of biological indicator evaluator resistometer vessels used to measure the resistance of bacterial spores in monitoring sterilization processes.


Pharmaceutical Technology


Materials and methods


Figure 4
Resistometers . The Fedegari-manufactured resistometer is a model FOB 3 steam sterilizer (140 L) fitted with a device that allows the rapid insertion and removal of BIs into the chamber while charged and under pressure (see Figure 4). The device consists of a loading chamber, a guiding tube through the main chamber, and an exit chamber. The loading chamber is positioned on top of the resistometer. The biological indicators are gravity-fed through the vessel by the precise coordination of the series of valves. The system is computer controlled and allows the operator to program the exposure time. The system is capable of running prevacuum cycles by evacuation of the loading chamber before insertion of the BIs into the main chamber. A Kaye Digistrip datalogger using 10 thermocouples was used to monitor the chamber temperature.

The Steris (Joslyn)-manufactured resistometers (model SB-001 and model JS-BIER-STM, Steris Corp., Mentor, OH) meet the performance requirements as described in ANSI/AAMI/ISO 18472:2006. Only the load probe of the resistometers was used to monitor chamber temperature.


Table I. Description of biological indicators (BIs).
Parametric analysis. In each resistometer, exposures were performed in triplicate at temperatures from 121 to 129 °C. Parametric data collected from these cycles were analyzed using the ANSI/AAMI/ISO standard as guidance.


Figure 5
Biological indicators . Three types of BIs—spore strip, self-contained, and glass ampul—from three manufacturers were used (see Table I). Spore-strip BIs consisted of Geobacillus stearothermophilus spores inoculated onto paper carriers and packaged in glassine envelopes. Self-contained BIs consisted of G. stearothermophilus spores inoculated onto paper carriers placed into a thermoplastic vial that serves as a culture tube. A small glass ampul containing sterile culture medium and color indicator also was in the vial. Glass-ampul BIs consisted of G. stearothermophilus spores suspended in liquid culture medium and sealed inside a small, thin-walled, pharmaceutical-grade glass ampul. BIs were loaded into a cassette (see Figure 5) before insertion into the chamber. Upon completion of the cycle, the cassette was removed from the chamber.

D and Z value analysis. Spore strip survivor curve. In the Fedegari and Steris (JS-BIER-STM) resistometers, D 121-values were determined (in triplicate) on the spore strip BIs by the survivor-curve method according to ISO 11138 (2). The survivor-curve method involves subjecting the BIs to a series of incremental exposure times followed by enumeration of the surviving spores through the performance of a population assay. This method was chosen for the simplest BIs to evaluate the linearity of the curve in each resistometer. Testing was as follows:

  • BI lot# S1—D 121-value determined in triplicate in Fedegari resistometer
  • BI lot# S1—D 121-value determined in triplicate in Steris (JS-BIER-STM) resistometer.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
42%
Facility/environment problems
0%
Process development problems
8%
Production equipment downtime
8%
Raw material supply problems
25%
Regulatory restrictions
0%
Business decisions to limit production
17%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Patent Settlements Become More Risky
Praise and Perils for Biotechnology Patent Policy
Risk-Mitigation Strategies in Drug Manufacturing for Emerging Markets
Quality Focus: Ensuring Raw Material Transparency
Advertising of Prescription Drugs  Keeping it Honest and Balanced
Source: Pharmaceutical Technology,
Click here